Akermansia muciniphila
shows promise as a next-generation probiotic, however, its beneficial regulatory effects on mice ulcerative colitis (UC) has not been extensively investigated. We used an
Akkermansia muciniphila
strain (AKK ONE) isolated from healthy human feces to study its effect on DSS-induced colitis in mice. Our results demonstrate that AKK ONE supplementation significantly improves food intake, weight, colon length, disease activity index (DAI) score, organ index, and tissue damage of colitis mice. AKK ONE notably improved intestinal barrier integrity by significantly enhancing expression of occludin and claudin-1. Additionally, AKK ONE reduced inflammation by down-regulating IL-1β, IL-6, and TNF-α, and up-regulating IL-10. In addition to reducing excessive inflammation, AKK ONE also increased the abundance of
Akkermansia
and decreased the abundance of
Bacteroides
. Furthermore, the AKK ONE intervention markedly increased SCFAs in cecal contents. AKK ONE may be a potential therapeutic agent for improving UC, based on the findings of this study.